Literature DB >> 3480843

Contributions of transcriptional and post-transcriptional mechanisms to the regulation of c-myc expression in mouse erythroleukemia cells.

A Nepveu1, K B Marcu, A I Skoultchi, H M Lachman.   

Abstract

Chemically induced differentiation of mouse erythroleukemia (MEL) cells leads to complex changes in c-myc mRNA levels. Within 1-2 hr after the addition of the inducer hexamethylene bisacetamide (HMBA), c-myc mRNA levels decrease 10- to 20-fold and remain low until 12-24 hr, at which time the mRNA reaccumulates to its original level. Thereafter as the cells undergo terminal differentiation, c-myc mRNA again declines to a low level. We have investigated the regulation of these changes by measuring c-myc gene transcription and mRNA turnover. We find that the early rapid decline in c-myc mRNA is due to an increase in the block to elongation of transcription within the c-myc first exon. Effective c-myc transcription is then restored after 2 hr of HMBA treatment to the level present in uninduced cells and is maintained throughout the remainder of the differentiation program. These results demonstrate that, except for the rapid decline in c-myc mRNA immediately following inducer treatment, all subsequent regulation of message levels occurs through post-transcriptional mechanisms. Studies of c-myc mRNA turnover suggest that some post-transcriptional regulation is nuclear.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3480843     DOI: 10.1101/gad.1.9.938

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  26 in total

1.  A cis-acting element in the promoter region of the murine c-myc gene is necessary for transcriptional block.

Authors:  H Miller; C Asselin; D Dufort; J Q Yang; K Gupta; K B Marcu; A Nepveu
Journal:  Mol Cell Biol       Date:  1989-12       Impact factor: 4.272

2.  Zinc finger protein 746 promotes colorectal cancer progression via c-Myc stability mediated by glycogen synthase kinase 3β and F-box and WD repeat domain-containing 7.

Authors:  Ji Hoon Jung; Deok-Beom Jung; Hyunseok Kim; Hyemin Lee; Shi-Eun Kang; Sanjay K Srivastava; Miyong Yun; Sung-Hoon Kim
Journal:  Oncogene       Date:  2018-04-09       Impact factor: 9.867

3.  Serum-inducible expression of transfected human c-myc genes.

Authors:  A Richman; A Hayday
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

4.  cis-acting translational effects of the 5' noncoding region of c-myc mRNA.

Authors:  N Parkin; A Darveau; R Nicholson; N Sonenberg
Journal:  Mol Cell Biol       Date:  1988-07       Impact factor: 4.272

5.  Regulation of c-myc mRNA stability in vitro by a labile destabilizer with an essential nucleic acid component.

Authors:  G Brewer; J Ross
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

6.  c-myc, c-fos, and c-jun regulation in the regenerating livers of normal and H-2K/c-myc transgenic mice.

Authors:  D Morello; M J Fitzgerald; C Babinet; N Fausto
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

7.  Somatic mutation and transcriptional deregulation of myc in endemic Burkitt's lymphoma disease: heptamer-nonamer recognition mistakes?

Authors:  B Morse; V J South; P G Rothberg; S M Astrin
Journal:  Mol Cell Biol       Date:  1989-01       Impact factor: 4.272

8.  Regulated expression of genes inserted at the human chromosomal beta-globin locus by homologous recombination.

Authors:  A K Nandi; R S Roginski; R G Gregg; O Smithies; A I Skoultchi
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

9.  Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a posttranscriptional mechanism.

Authors:  S Guilhot; L G Guidotti; F V Chisari
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

10.  Premature termination of transcription from the P1 promoter of the mouse c-myc gene.

Authors:  S Wright; L F Mirels; M C Calayag; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.